← Back to Search

Sphingosine-1-phosphate receptor modulator

Ponesimod 10 mg for Multiple Sclerosis

Phase 2
Waitlist Available
Research Sponsored by Actelion
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 660 weeks (core plus extension)
Awards & highlights

Study Summary

This trial will study the long-term effects of ponesimod, a drug used to treat relapsing-remitting multiple sclerosis.

Eligible Conditions
  • Multiple Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 660 weeks (core plus extension)
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 660 weeks (core plus extension) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Annualized confirmed relapse rate
Time to 24 Weeks Confirmed Disability Progression up to end of the study
Time to first confirmed relapse
Other outcome measures
(Serious) Adverse Events

Trial Design

3Treatment groups
Experimental Treatment
Group I: Ponesimod 40 mgExperimental Treatment1 Intervention
Ponesimod 40 mg oral use
Group II: Ponesimod 20 mgExperimental Treatment1 Intervention
Ponesimod 20 mg oral use
Group III: Ponesimod 10 mgExperimental Treatment1 Intervention
Ponesimod 10 mg oral use
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ponesimod 40 mg
2011
Completed Phase 2
~470
Ponesimod 20 mg
2011
Completed Phase 2
~470
Ponesimod 10 mg
2011
Completed Phase 2
~470

Find a Location

Who is running the clinical trial?

ActelionLead Sponsor
191 Previous Clinical Trials
35,340 Total Patients Enrolled
4 Trials studying Multiple Sclerosis
2,610 Patients Enrolled for Multiple Sclerosis

Media Library

Ponesimod 10 mg (Sphingosine-1-phosphate receptor modulator) Clinical Trial Eligibility Overview. Trial Name: NCT01093326 — Phase 2
Multiple Sclerosis Research Study Groups: Ponesimod 10 mg, Ponesimod 40 mg, Ponesimod 20 mg
Multiple Sclerosis Clinical Trial 2023: Ponesimod 10 mg Highlights & Side Effects. Trial Name: NCT01093326 — Phase 2
Ponesimod 10 mg (Sphingosine-1-phosphate receptor modulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01093326 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research project require participants to be over the age of 20?

"The age range for this study is 18-55, as outlined in the eligibility requirements."

Answered by AI

What is the estimated sample size for this trial?

"This trial is not enrolling patients at the moment, although it was accepting them in the past. The last date that information on the trial was updated was November 8th, 2022. There are currently 564 other trials for multiple sclerosis and 3 studies involving Ponesimod 10 mg that are looking for participants."

Answered by AI

Who meets the eligibility requirements for this clinical trial?

"This trial, which is looking for 353 participants, is only open to patients that have multiple sclerosis and are between 18-55 years old."

Answered by AI

Are there any other scientific studies that have used Ponesimod 10 mg?

"Ponesimod 10 mg is being trialed in 3 active studies, one of which has reached Phase 3. Many of the clinical trials for Ponesimod 10 mg are based in Chernihiv and Florida, with a total of 252 locations running tests."

Answered by AI

Has Ponesimod 10 mg received FDA sanctioning?

"Ponesimod 10 mg is currently in Phase 2 of clinical trials. While there is promising safety data, there is no evidence yet that the medication is effective."

Answered by AI

Can patients still sign up for this research project?

"Unfortunately, this particular study is not presently looking for new patients. Although the trial was most recently updated on November 8th 2022, it is not currently recruiting. However, there are 567 other trials that might be a better match for you and which are actively searching for participants right now."

Answered by AI

Is this trial available in many locations around the city?

"There are a total of 17 clinical trial sites for this study. The locations include Venice, Kansas City and Latham. There may be other centres near you, so it is advised that patients enroll at the closest location to minimize travel requirements."

Answered by AI

What is the historical context of this clinical trial?

"Ponesimod 10 mg has been studied since 2010 when it was first trialled by Actelion. The drug progressed to Phase 2 after the successful initial study of 353 in 2010. Ponesimod 10 mg is currently being trialled in 31 countries and 52 cities."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
2010. "Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01093326.
~24 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top